These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34213819)

  • 21. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Cosentino F; Cannon CP; Cherney DZI; Masiukiewicz U; Pratley R; Dagogo-Jack S; Frederich R; Charbonnel B; Mancuso J; Shih WJ; Terra SG; Cater NB; Gantz I; McGuire DK;
    Circulation; 2020 Dec; 142(23):2205-2215. PubMed ID: 33026243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pooled Population Pharmacokinetic Analyses of Venetoclax in Patients Across Indications and Healthy Subjects from Phase 1, 2, and 3 Clinical Trials.
    Gong JQX; Suleiman AA; Menon R; Deng R; Mensing S; Salem AH
    J Clin Pharmacol; 2023 Aug; 63(8):950-960. PubMed ID: 37055934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population Pharmacokinetics of Eplerenone in Japanese Patients With Chronic Heart Failure.
    Oishi M; Tomono Y; Zhao Q; Sweeney K
    J Clin Pharmacol; 2017 Jun; 57(6):730-738. PubMed ID: 28032902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ertugliflozin: A New Option in the SGLT-2 Inhibitor Market for the Treatment of Type 2 Diabetes Mellitus.
    Powell J; Garland SG
    Ann Pharmacother; 2019 May; 53(5):478-485. PubMed ID: 30522346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies.
    Liu J; Tarasenko L; Terra SG; Huyck S; Wu L; Pong A; Calle RA; Gallo S; Darekar A; Mancuso JP
    Diab Vasc Dis Res; 2019 Sep; 16(5):415-423. PubMed ID: 31081371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ertugliflozin as a monotherapy for the treatment of type 2 diabetes.
    Hu J; Deng A; Zhao Y
    Expert Opin Pharmacother; 2018 Nov; 19(16):1841-1847. PubMed ID: 30223693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview.
    Dash RP; Babu RJ; Srinivas NR
    Xenobiotica; 2017 Nov; 47(11):1015-1026. PubMed ID: 27718782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
    Rosenstock J; Frias J; Páll D; Charbonnel B; Pascu R; Saur D; Darekar A; Huyck S; Shi H; Lauring B; Terra SG
    Diabetes Obes Metab; 2018 Mar; 20(3):520-529. PubMed ID: 28857451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ertugliflozin for treatment of patients with Type 2 diabetes mellitus.
    Yang J
    Expert Rev Clin Pharmacol; 2018 Aug; 11(8):747-753. PubMed ID: 30025475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Henagliflozin, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter 2, in Healthy Subjects Following Single- and Multiple-dose Administration.
    Zhang YF; Liu YM; Yu C; Wang YT; Zhan Y; Liu HY; Zou JJ; Jia JY; Chen Q; Zhong DF
    Clin Ther; 2021 Feb; 43(2):396-409. PubMed ID: 33454124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioequivalence of Ertugliflozin/Metformin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components.
    Dawra VK; Liang Y; Wei H; Pelletier K; Shi H; Hickman A; Bass A; Terra SG; Zhou S; Krishna R; Sahasrabudhe V
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):50-61. PubMed ID: 31207178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus.
    Liu J; Tarasenko L; Pong A; Huyck S; Patel S; Hickman A; Mancuso JP; Ellison MC; Gantz I; Terra SG
    Curr Med Res Opin; 2020 Jul; 36(7):1097-1106. PubMed ID: 32324065
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
    Terra SG; Focht K; Davies M; Frias J; Derosa G; Darekar A; Golm G; Johnson J; Saur D; Lauring B; Dagogo-Jack S
    Diabetes Obes Metab; 2017 May; 19(5):721-728. PubMed ID: 28116776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ertugliflozin for the treatment of type 2 diabetes.
    Sharma R; Razdan K; Kuhad A; Kuhad A
    Drugs Today (Barc); 2019 Mar; 55(3):167-175. PubMed ID: 30938372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.
    Aronson R; Frias J; Goldman A; Darekar A; Lauring B; Terra SG
    Diabetes Obes Metab; 2018 Jun; 20(6):1453-1460. PubMed ID: 29419917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies.
    Pratley R; Dagogo-Jack S; Charbonnel B; Patel S; Hickman A; Liu J; Tarasenko L; Pong A; Ellison MC; Huyck S; Gantz I; Terra SG
    Diabetes Obes Metab; 2020 Dec; 22(12):2276-2286. PubMed ID: 32700421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
    Cannon CP; Pratley R; Dagogo-Jack S; Mancuso J; Huyck S; Masiukiewicz U; Charbonnel B; Frederich R; Gallo S; Cosentino F; Shih WJ; Gantz I; Terra SG; Cherney DZI; McGuire DK;
    N Engl J Med; 2020 Oct; 383(15):1425-1435. PubMed ID: 32966714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
    Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B
    Diabetes Obes Metab; 2018 May; 20(5):1111-1120. PubMed ID: 29266675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus.
    Heymsfield SB; Raji A; Gallo S; Liu J; Pong A; Hannachi H; Terra SG
    Obesity (Silver Spring); 2020 Apr; 28(4):724-732. PubMed ID: 32202075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.
    Amin NB; Wang X; Jain SM; Lee DS; Nucci G; Rusnak JM
    Diabetes Obes Metab; 2015 Jun; 17(6):591-598. PubMed ID: 25754396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.